[KRP-297, MCC-555].
T Yamanouchi
Index: Nihon Rinsho. 59(11) , 2200-6, (2001)
Full Text: HTML
Abstract
KRP-297 and MCC-555, which are being developed in Japan as thiazolidinediones, uniquely bind and activate peroxisome proliferator-activated receptors(PPAR). KRP-297, unlike other thiazolidinediones, effects on not only PPAR gamma but also PPAR alpha. Furthermore, this compound acts directly on basal glucose uptake in the rat skeletal muscle. KRP-297 decreased plasma glucose and insulin levels, and also blood triglyceride and free fatty acid in diabetic animal models. MCC-555 has significant antidiabetic properties yet its binding affinity for PPAR gamma is less than 1/10 that of BRL 49653. Thus, it is regarded now as a PPAR gamma modulator rather than agonist, depending on cell type. At present, clinical phase II studies of both drugs are under way.
Related Compounds
Related Articles:
MCC-555-induced NAG-1 expression is mediated in part by KLF4.
2010-07-10
[Eur. J. Pharmacol. 637(1-3) , 30-7, (2010)]
2003-04-01
[Int. J. Exp. Pathol. 84(2) , 83-9, (2003)]
Activation of PPARgamma is not involved in butyrate-induced epithelial cell differentiation.
2005-10-15
[Exp. Cell Res. 310(1) , 196-204, (2005)]
2006-05-01
[J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 835(1-2) , 35-9, (2006)]
1999-03-01
[Nihon Rinsho. 57(3) , 688-94, (1999)]